Updated: Delfi Diagnostics hires Illumina’s chief commercial officer as next CEO
Delfi Diagnostics has hired Susan Tousi, Illumina’s chief commercial officer, as its new CEO, the company confirmed Friday in a press release.
Delfi is a competitor to Illumina’s Grail unit, which Illumina is in the process of divesting. Like Grail, it makes a blood-based cancer test that aims to catch malignancies early. The test it sells is meant to detect lung cancer, unlike Grail’s, which looks for a wider set of tumor types.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.